Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

N Engl J Med. 2024 Oct 10;391(14):1364. doi: 10.1056/NEJMc2410841.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized* / administration & dosage
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Boron Compounds / administration & dosage
  • Boron Compounds / adverse effects
  • Bortezomib* / administration & dosage
  • Bortezomib* / adverse effects
  • Clinical Trials, Phase III as Topic
  • Corneal Diseases* / chemically induced
  • Corneal Diseases* / epidemiology
  • Dexamethasone* / administration & dosage
  • Dexamethasone* / adverse effects
  • Humans
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / mortality
  • Progression-Free Survival
  • Randomized Controlled Trials as Topic

Substances

  • Antibodies, Monoclonal, Humanized
  • belantamab mafodotin
  • Boron Compounds
  • Bortezomib
  • Dexamethasone